In addition, by identifying cediranib as another agent that is synthetically lethal to IDH1-mutant cancers, and that can resensitize these resistant cancer cells to PARPi, this work may also provide the basis for new therapeutic strategies for patients with oncometabolite-producing malignancies. Here, IDH1 is linked to cancer.